TCH方案新辅助化疗在HER-2阳性早期乳腺癌治疗中的效果及对患者脂质运载蛋白-2表达的影响  

Application of TCH Regimen Neoadjuvant Chemotherapy in HER-2 Positive Early Breast Cancer and Its Effect on Expression of Lipocalin-2

作　　者：余花艳 史中州 仓顺东[2] YU Huayan;SHI Zhongzhou;CANG Shundong(Pingdingshan Second People's Hospital,Pingdingshan,467000)

机构地区：[1]河南省平顶山市第二人民医院,467000 [2]河南省人民医院,450003

出　　处：《实用癌症杂志》2021年第3期483-485,493,共4页The Practical Journal of Cancer

摘　　要：目的探究TCH方案新辅助化疗在人类表皮生长因子受体-2(HER-2)阳性早期乳腺癌治疗中的效果,并分析其对脂质运载蛋白-2(LCN-2)表达的影响。方法选取早期乳腺癌患者86例,据治疗方案的不同将其分为对照组、观察组,各43例。对照组给予TAC方案新辅助化疗,观察组给予TCH方案新辅助化疗,2组化疗时间均为6个疗程。统计2组患者化疗后的临床疗效;比较2组患者化疗前后血清LCN-2水平的差异;观察并统计2组患者化疗期间的不良反应发生情况。结果化疗后,观察组临床总有效率为60.47%,高于对照组的88.37%(P<0.05)。化疗后,2组血清LCN-2水平降低,且观察组低于对照组(P<0.01)。对照组和观察组患者化疗期间不良反应发生率分别为62.79%、44.19%,在统计学上无差异(P>0.05)。化疗12个月后2组患者总生存率达100%。结论TCH方案新辅助化疗可降低HER-2阳性早期乳腺癌患者血清LCN-2水平,提高临床疗效,安全性高,值得推广。Objective To explore the application of TCH regimen neoadjuvant chemotherapy in human epidermal growth factor receptor-2(HER-2)positive early breast cancer,and to analyze its effect on the expression of lipocalin-2(LCN-2).Methods 86 patients with early breast cancer were retrospectively selected.According to different treatment plans,they were divided into the control group and the observation group,43 cases in each group.The control group was given neoadjuvant chemotherapy of TAC regimen,and the observation group was given neoadjuvant chemotherapy of TCH regimen.The duration of chemotherapy in both groups was 6 courses.The clinical efficacy of the 2 groups was counted one month after chemotherapy,the difference of serum LCN-2 levels between the 2 groups before and after chemotherapy were compared,and the adverse reactions during chemotherapy were observed and statistically analyzed.Results After chemotherapy,the total clinical effective rate in the observation group was 60.47% higher than that in the control group(88.37%)(P<0.05).After chemotherapy,the serum LCN-2 level in the 2 groups decreased,and that in the observation group was lower than that of the control group(P<0.01).The rates of adverse reactions during chemotherapy in the control group and the observation group were 62.79% and 44.19%,respectively,there had no statistical difference(P>0.05).12 months after chemotherapy,the overall survival rate of the 2 groups was 100%.Conclusion TCH regimen neoadjuvant chemotherapy can reduce the serum LCN-2 level of HER-2 positive early breast cancer patients,improve the clinical efficacy,and has high safety,which is worth popularizing.

关 键 词：早期乳腺癌 新辅助化疗 人类表皮生长因子受体-2 脂质运载蛋白-2 

分 类 号：R737.9[医药卫生—肿瘤]